Silence Therapeutics plc

DB:XRP2 Stock Report

Market Cap: €307.6m

Silence Therapeutics Management

Management criteria checks 2/4

Silence Therapeutics' CEO is Craig Tooman, appointed in Feb 2022, has a tenure of 2.92 years. total yearly compensation is £7.30M, comprised of 6.5% salary and 93.5% bonuses, including company stock and options. directly owns 0.024% of the company’s shares, worth €72.71K. The average tenure of the management team and the board of directors is 2.3 years and 4.9 years respectively.

Key information

Craig Tooman

Chief executive officer

UK£7.3m

Total compensation

CEO salary percentage6.5%
CEO tenure2.9yrs
CEO ownership0.02%
Management average tenure2.3yrs
Board average tenure4.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Craig Tooman's remuneration changed compared to Silence Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-UK£59m

Jun 30 2024n/an/a

-UK£40m

Mar 31 2024n/an/a

-UK£35m

Dec 31 2023UK£7mUK£473k

-UK£43m

Sep 30 2023n/an/a

-UK£43m

Jun 30 2023n/an/a

-UK£41m

Mar 31 2023n/an/a

-UK£43m

Dec 31 2022UK£6mUK£461k

-UK£40m

Sep 30 2022n/an/a

-UK£36m

Jun 30 2022n/an/a

-UK£39m

Mar 31 2022n/an/a

-UK£39m

Dec 31 2021UK£2mUK£334k

-UK£39m

Compensation vs Market: Craig's total compensation ($USD9.02M) is above average for companies of similar size in the German market ($USD981.65K).

Compensation vs Earnings: Craig's compensation has increased whilst the company is unprofitable.

CEO

Craig Tooman (59 yo)

2.9yrs

Tenure

UK£7,298,000

Compensation

Mr. Craig A. Tooman, MBA, serves as President, Chief Executive Officer and Executive Director of Silence Therapeutics plc since February 21, 2022. He has been a Supervisory Director of Curevac N. V. since...

Leadership Team

NamePositionTenureCompensationOwnership
Craig Tooman
President2.9yrsUK£7.30m0.024%
€ 72.7k
Rhonda Hellums
Executive VP2.9yrsUK£2.50m0.0011%
€ 3.3k
Steven Romano
Executive VP and Chief Research & Development Officer1.8yrsUK£1.82m0.0092%
€ 28.2k
Marie Lindholm
Chief Scientific Officer1.1yrsno datano data
Gem Hopkins
Head of IR & Corporate Communicationsno datano datano data
Gianine Esposito
Chief Human Resources Officerless than a yearno datano data
Barbara Ruskin
Senior VP and Chief Intellectual Property & Innovation Officer2.3yrsno datano data
Eric Floyd
Senior Vice President of Regulatory Affairs & Quality Assurance4.5yrsno datano data
J.P. Gabriel
Chief Technical Operations Officer2.2yrsno datano data
Curtis Rambaran
Chief Medical Officerno datano datano data

2.3yrs

Average Tenure

61yo

Average Age

Experienced Management: XRP2's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Craig Tooman
President2.9yrsUK£7.30m0.024%
€ 72.7k
David Lemus
Independent Non-Executive Director6.6yrsUK£184.00k0.0053%
€ 16.3k
Gordon Duff
Chairman of Scientific Advisory Board4.9yrsno datano data
Michael Davidson
Independent Non-Executive Director4yrsUK£178.00k0.0092%
€ 28.2k
Iain Ross
Independent Chairman of the Board5.8yrsUK£402.00k0.078%
€ 238.7k
John Porter
Member of Scientific Advisory Board4.9yrsno datano data
James Ede-Golightly
Independent Non-Executive Director5.8yrsUK£182.00k0.011%
€ 32.6k
Henry Ginsberg
Member of Scientific Advisory Board4.9yrsno datano data
Annemieke Aartsma-Rus
Member of Scientific Advisory Board4.9yrsno datano data
John Whittaker
Member of Scientific Advisory Board4.6yrsno datano data
Jenny Sims
Member of Scientific Advisory Board3yrsno datano data
Tom Brown
Member of Scientific Advisory Board3yrsno datano data

4.9yrs

Average Tenure

62yo

Average Age

Experienced Board: XRP2's board of directors are considered experienced (4.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 01:05
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Silence Therapeutics plc is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBMO Capital Markets Equity Research
Konstantinos BiliourisBMO Capital Markets Equity Research
Thomas ShraderBTIG